Literature DB >> 20858960

Alzheimer's disease: a general introduction and pathomechanism.

Verena H Finder1.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia, which affects more than 35 million people worldwide with increasing tendency. Satisfying therapies and prevention are not available. Since the first description of the fatal progressive neurodegenerative disease in 1907, however, major findings on the molecular mechanisms have been reported. Current clinical trials target diverse aspects and principles of AD, such as the generation and aggregation of amyloid-β (Aβ). Extracellular amyloid plaques, predominantly consisting of Aβ, and intracellular neurofibrillar tangles, formed by hyperphosphorylated tau, are the major pathological hallmarks in the brain of AD patients. AD is consequently one of about 40 identified amyloidoses - protein misfolding diseases, which share as their main pathogenic mechanism the aberrant deposition of endogenous proteins as amyloid fibrils. This article aims principally to introduce AD and its identified key players, to summarize classic and recent publications on the complex molecular mechanisms underlying the disease, and to discuss challenges that need to be faced for the development of improved therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858960     DOI: 10.3233/JAD-2010-100975

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  38 in total

1.  Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits.

Authors:  Jogender Mehla; Balwantsinh C Chauhan; Neelima B Chauhan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  Identification of new BACE1 inhibitors for treating Alzheimer's disease.

Authors:  Pragya Kushwaha; Vineeta Singh; Pallavi Somvanshi; Tulika Bhardwaj; George E Barreto; Ghulam Md Ashraf; Bhartendu Nath Mishra; Rajendra Singh Chundawat; Shafiul Haque
Journal:  J Mol Model       Date:  2021-01-30       Impact factor: 1.810

Review 3.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

Review 4.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

5.  Charge dependent retardation of amyloid β aggregation by hydrophilic proteins.

Authors:  Anna Assarsson; Erik Hellstrand; Celia Cabaleiro-Lago; Sara Linse
Journal:  ACS Chem Neurosci       Date:  2014-02-06       Impact factor: 4.418

6.  Structure-Activity Relationships and in Vivo Evaluation of Quinoxaline Derivatives for PET Imaging of β-Amyloid Plaques.

Authors:  Masashi Yoshimura; Masahiro Ono; Kenji Matsumura; Hiroyuki Watanabe; Hiroyuki Kimura; Mengchao Cui; Yuji Nakamoto; Kaori Togashi; Yoko Okamoto; Masafumi Ihara; Ryosuke Takahashi; Hideo Saji
Journal:  ACS Med Chem Lett       Date:  2013-05-21       Impact factor: 4.345

Review 7.  Imaging biomarkers associated with cognitive decline: a review.

Authors:  Jonathan McConathy; Yvette I Sheline
Journal:  Biol Psychiatry       Date:  2014-09-16       Impact factor: 13.382

Review 8.  Oxidative stress and β-amyloid protein in Alzheimer's disease.

Authors:  Zhiyou Cai; Bin Zhao; Anna Ratka
Journal:  Neuromolecular Med       Date:  2011-09-08       Impact factor: 3.843

9.  Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice.

Authors:  Neelima B Chauhan; Francesca Davis; Chun Xiao
Journal:  Vaccine       Date:  2011-08-12       Impact factor: 3.641

Review 10.  Opioid system and Alzheimer's disease.

Authors:  Zhiyou Cai; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-04-22       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.